Abstract
A method for treating or alleviating autoimmune encephalitis with an effective amount of a medicament targeting Blys and/or APRIL. Results show that the effective amount of the medicament targeting Blys and/or APRIL exhibits a good safety profile and a relatively good therapeutic effect in the process of treating or alleviating autoimmune encephalitis.
Full Text
What is claimed is:
A method for treating or alleviating autoimmune encephalitis with an effective amount of a medicament targeting Blys and/or APRIL. Results show that the effective amount of the medicament targeting Blys and/or APRIL exhibits a good safety profile and a relatively good therapeutic effect in the process of treating or alleviating autoimmune encephalitis.
Timeline
Filed
04/24/2026Published
08/20/2026Granted
Not AvailableIPC Codes(5)
C07K 14/705:Receptors; Cell surface antigens; Cell surface determinants
A61K 9/00:Medicinal preparations characterised by special physical form
A61K 38/00:Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K 31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K 31/00; ergoline-based peptides A61K 31/48; containing macromolecular compounds having statistically distributed amino acid units A61K 31/74; medicinal preparations containing antigens or antibodies A61K 39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K 47/00)